Kwality Pharmaceuticals FY26: Growth, Margins, and a Larger Regulated Market Push

/n# Kwality Pharmaceuticals FY26: Growth, Margins, and a Larger Regulated Market Push/n/nKwality Pharmaceuticals closed FY26 with its strongest annual performance so far. Consolidated revenue rose to INR503.1 crore in FY26 from INR370.2 crore in FY25. EBITDA increased to INR118.3 crore with an EBITDA margin of 24.0%, up from 21.6% in FY25. Profit after tax climbed to INR67.4 crore from INR39.8 crore, taking PAT margin to 13.4% from 10.8%. The company described FY26 as a year where it delivered on commitments communicated earlier, supported by export execution and operating discipline./n/nThe momentum was visible in Q4 as well. Q4FY26 revenue was INR157.1 crore versus INR115.6 crore in Q4FY25. EBITDA rose to INR38.8 crore with margin at 24.6%, and PAT increased to INR25.3 crore with margin at 16%. Management attributed margin improvement to better operational efficiency, improved realizations, and cost discipline, while also flagging that geopolitical disruptions temporarily affected working capital cycles./n/n## What drove FY26 performance/n/nThe company operates largely through an out-licensing and supply model. The investor deck states that out-licensing and supply accounts for 90% of revenue, while CDMO contributes 10%. This model supports wide geographic reach across 70 plus markets, with growth linked to filings and registrations rather than building large front-end commercial teams./n/nProduct mix is heavily tilted toward injectables and solid orals. For FY26, the deck reports revenue share by type as injectables at 48% and tablets at 38%, with the balance spread across capsules, liquids, creams, dry syrups, ophthalmic, sachets, and suppositories. Unit-wise, FY26 revenue split is reported as Unit 1 General at 60%, Unit 3 Oncology at 26%, Unit 2 Beta Lactam at 10%, and Unit 4 Cephalosporins at 4%./n/nManagement also provided an oncology revenue indicator in the concall. It stated oncology contributed roughly INR100 crore in FY26 and is expected to scale to INR150 crore in FY27 and up to INR300 crore by FY29./n/n| Metric | FY25 | FY26 | Change |/n|---|---:|---:|---:|/n| Revenue (INR crore) | 370.2 | 503.1 | 46% |/n| EBITDA (INR crore) | 80.4 | 118.3 | 47% |/n| EBITDA margin | 21.6% | 24.0% | +240 bps |/n| PAT (INR crore) | 39.8 | 67.4 | 72% |/n| PAT margin | 10.8% | 13.4% | +260 bps |/n/n## Capacity, compliance, and the oncology expansion plan/n/nA key narrative across both the presentation and concall is the company’s regulatory positioning. The deck highlights that 4 out of 5 manufacturing units are EU GMP approved, and it points to more than 20 regulatory, customer, and vendor audits over the past two years. It also mentions benchmarking plant practices against industry Form 483 observations and using a centralized corporate quality assurance team to drive consistent compliance across facilities./n/nOncology is a major value driver in the medium-term plan. Management explained in the concall that changes in European Annex 1 guidelines increased changeover and validation requirements, which reduced effective throughput and required immediate facility expansion. It cited an allocation of around INR50 crore to expand oncology capacity, aligned with the company’s FY29 ambition./n/nThe deck lists specific actions in Unit 3 Oncology. These include two new lyophilizers of 20 cubic meters each, a lyophilizer with automatic loading and unloading, and an injectable filling line with complete isolators. Management also discussed oncology margins. It indicated peptide oncology products can deliver about 40% EBITDA margin, routine oncology about 25%, and a blended oncology EBITDA margin near 32% as peptide share rises./n/n## Biologics and hormones: optional upside, but capex is real/n/nBiologics is positioned as the next platform. The investor deck lays out a milestone tracker for Erythropoietin biosimilar, branded as Kwalipoietin. It shows successful pre-clinical results in Q2 FY26, approval for clinical trials in Q3 FY26, Phase III in Q1 FY27, regulatory submission targeted in Q2 FY27, and commercial launch targeted in H1 FY27. A broader pipeline is also disclosed: Pembrolizumab with proof of concept achieved and other mAbs such as Nivolumab and Pertuzumab in earlier stages./n/nIn the concall, management cautioned that biologics timelines can depend on CDSCO approvals. It stated that it expects to submit clinical data by October or November and then wait for approvals, implying that registration timelines are not fully in its control./n/nUnit 6, the hormone facility, is another major project. The deck provides a detailed tracker with civil construction at 90%, equipment procurement at 80%, installation at 30%, utilities at 10%, recruitment at 5%, and R&D at 20%. The roadmap targets validation runs in Q2 FY27, WHO or PICS GMP audit in Q3 FY27, and commercial production in Q3 FY27. Management said in the concall that total hormone capex is around INR65 crore and about half was spent in FY26./n/nA key management point is that the FY29 revenue aspiration of INR1,000 crore does not include hormones and biologics. Management stated hormones could reach INR100 to INR150 crore by FY29 in unregulated and semi-regulated markets, and EPO in India alone could contribute INR80 to INR100 crore by FY29, but these numbers were not included in the INR1,000 crore base plan. It described these as potential upside or contingency to protect the INR1,000 crore goal./n/n## Working capital: improving trend, but FY26 stress is visible/n/nThe deck reports cash conversion cycle improving from 297 days in FY23 to 161 days in FY26, supported by inventory discipline. It also shows FY26 ROE at 22.7% and ROCE at 31.2%./n/nHowever, FY26 cash flow and receivables need attention. Consolidated operating cash flow was INR16.6 crore in FY26 versus INR52.7 crore in FY25. The balance sheet in the deck shows trade receivables rising to INR280 crore in FY26 from INR154 crore in FY25. In the concall, management linked the spike to the Middle East and West Asia conflict conditions affecting shipping and payment cycles. It quantified that INR60 to INR70 crore was stuck for 1.5 to 2 quarters and said about 40% had already been recovered, with full recovery expected by June or July./n/nManagement also explained that parts of the MENA business are registered tender supplies with longer payment cycles and 100% credit, which structurally keeps receivable days elevated. This is important context for investors tracking cash conversion versus accounting profits./n/n## Guidance: FY27 targets, medium-term milestones, and capex plan/n Management reiterated FY27 guidance of INR650 crore revenue and INR100 crore PAT. It also said the INR650 crore target is conservative and revenue could be INR650 to INR700 crore depending on registration timelines, particularly in LATAM. For FY28, it indicated revenue could be INR800 to INR850 crore with around 28% EBITDA margin, and for FY29 it reiterated INR1,000 crore revenue and around 30% EBITDA margin.

The investor deck adds a FY27 revenue target slide with INR650 crore revenue, INR160 crore EBITDA and a 25% EBITDA margin, along with INR100 crore PAT.

On capex, the deck provides a segment view for FY26 to FY28. It shows oncology capex of INR5 crore in FY26, INR40 crore in FY27E, and INR5 crore in FY28E; biologics INR19 crore, INR22 crore, and INR70 crore; hormones INR15 crore, INR40 crore, and INR15 crore; and R&D INR7 crore, INR18 crore, and INR20 crore. In the concall, management described a broader capex program of about INR260 to INR270 crore across hormones, oncology expansion, biosimilar clinical trials, R&D, and BE programs. It stated FY27 capex could be around INR90 crore and FY28 capex around INR90 to INR100 crore.

Closing takeaways

FY26 reinforces Kwality Pharmaceuticals’ ability to grow revenue while expanding EBITDA and PAT margins. The company is leaning into an export-led, filing-driven model with a heavy mix of injectables and a rising oncology contribution. The medium-term plan relies on faster regulated market registrations, especially in Europe and LATAM, alongside capacity expansions in oncology.

At the same time, the working capital build-up in FY26 is a clear watch item. Management has acknowledged the reason and provided a recovery timeline, but the business model’s exposure to tender-like export markets can keep receivables elevated.

If execution stays on track, FY27 will be a key year to validate the next phase. The stated targets of INR650 crore revenue and INR100 crore PAT, along with a multi-year capex cycle in oncology, hormones, and biologics, set a clear scoreboard for investors to track./n